Dental Bone Graft Substitutes Market

The dental bone graft substitutes market is projected to reach USD 2.04 billion by 2031 from USD 1.40 billion in 2026, at a CAGR of 6.5% during the forecast period.

The global market for dental bone graft substitutes has been growing rapidly, driven primarily by the increasing incidence of tooth loss, periodontal diseases, and maxillofacial defects. As a result, there is a rising demand for more effective bone regeneration solutions. Both patients and doctors are becoming more aware of advanced dental restoration procedures. This awareness, combined with a greater use of dental implants, has significantly boosted the demand for these products.

To know about the assumptions considered for the study download the pdf brochure

Additionally, advancements in technologies for modifying graft materials, such as xenografts, allografts, and synthetic substitutes, have led to improved clinical outcomes and more predictable treatment results. These innovations also make it easier to apply these products, contributing to their growing popularity.

Moreover, the shift towards dental bone graft substitutes is supported by an aging population, increased dental tourism, and a greater emphasis on the aesthetics and functionality of oral rehabilitation. Collectively, these factors are driving the continuous expansion of the market worldwide.

The prominent players in the dental bone graft substitutes market include Dentsply Sirona (US), Envista (US), Johnson & Johnson (US), Institut Straumann AG (Switzerland), Medtronic (Ireland), ZimVie Inc. (US), Henry Schein Inc. (US), RTI Surgical (US), and LifeNet Health (US).

A major factor driving the dental bone graft substitutes market is the increasing prevalence of periodontal disease and edentulousness, which has led to a rise in dental implant procedures. As the rate of dental implant placement has risen, so has the need for bone augmentation, driving greater demand for bone substitutes.

Furthermore, advancements in the materials used in dentistry—such as new effective synthetic materials, xenograft materials, and bioactive materials—have improved the outcomes and convenience of these products, further driving market growth.

Additionally, increased awareness of oral health, growing interest in cosmetic and restorative dental treatments, and the trend towards less invasive, more efficient surgical procedures all contribute to the expansion of the market. In developed countries, favorable outcomes and reimbursement options also support this growth. Meanwhile, developing economies are witnessing an increase in dental healthcare services, with the establishment of new dental clinics and laboratories.

• In November 2025, Geistlich introduced Geistlich Bio-Gide Forte at the AAP annual meeting. This new product offers increased firmness, enhancing its handling during bone regeneration procedures. Additionally, Geistlich announced a flowable version of Geistlich Bio-Oss, set to launch in 2026. This new product combines collagen from both Geistlich Bio-Oss and Geistlich Bio-Gide, allowing for quicker application in bone regeneration.
• In February 2025, LifeNet Health developed OraGen, which provides viable dental bone allograft tissue. This includes cryopreserved corticocancellous bone with demineralized bone matrix and viable cells to achieve better osteogenic, osteoconductive, and osteoinductive outcomes for favorable dental reconstruction surgeries.

Dentsply Sirona (US)

Dentsply Sirona (US) is a leading global manufacturer of dental equipment and supplies. The company offers a wide range of products for restorative, preventive, prosthetic, and regenerative dental care. As a key player in the dental bone graft substitutes market, Dentsply Sirona continually evolves its expertise in dental biomaterials and clinical solutions. This commitment enables the development of dental bone graft products and adjunctive regenerative materials that facilitate guided bone regeneration (GBR) and implant therapy.

The company enjoys a strong reputation among dental practices and laboratories worldwide, supported by well-known brands, robust clinical relationships, and extensive distribution networks. These factors contribute to the widespread use of its bone graft substitutes. Dentsply Sirona focuses on research and development to improve product performance, enhance handling, and increase clinical predictability. Additionally, the company's implant systems, combined with regenerative solutions, give it a competitive edge.

Through innovative products, backed by education and global marketing support, Dentsply Sirona remains a major force in the development of bone-grafting procedures. The company effectively meets the needs of dental clinicians in both developed and emerging markets.

Envista (US)

Envista (US) is a global dental solutions company that offers a diverse portfolio of products, including dental implants, restoratives, digital dentistry tools, and regenerative materials. In the dental bone graft substitutes market, Envista capitalizes on its well-known brand and comprehensive product line to offer clinicians a range of bone graft and membrane solutions designed to promote bone regeneration and facilitate implant site development.

With a deep understanding of implantology and oral surgery, the company markets its graft materials as clinically relevant, ensuring they are specifically designed for bone augmentation and defect repair with predictable outcomes. Envista boasts an extensive distribution network, prompt customer service, and a strong emphasis on education and training, which together lead to its bone graft substitutes being widely adopted by dental professionals.

Through continuous investment in research and development and the establishment of strategic partnerships, Envista has successfully expanded its portfolio of regenerative products and strengthened its market position across established sectors and the dental industry.

MARKET RANKING

In the global dental bone graft substitutes market, Dentsply Sirona (US) holds the top position due to its comprehensive regenerative dentistry portfolio, extensive range of biomaterials, and an integrated digital and clinical ecosystem that facilitates guided bone regeneration (GBR) and related implant grafting procedures. Following closely is Envista (US), which ranks second due to its wide array of regenerative solutions, membranes, and biomaterial brands, combined with strong clinician adoption and a robust global distribution network.

Johnson & Johnson (US) ranks third due to its deep expertise in medical biomaterials and tissue regeneration technologies, and a strong research and development (R&D) department focused on dental and regenerative applications. Institut Straumann AG (Switzerland) is also a prominent player, known for its well-established brand in regenerative therapies, including bone graft substitutes, membranes, and integrated treatment solutions for implants, which are trusted worldwide.

Medtronic (Ireland) and ZimVie Inc. (US) are mid-tier companies that capitalize on their proficiency in biomaterials, surgical regeneration, and technologies for implant grafting. Henry Schein Inc. (US) maintains a leading position through its extensive global dental distribution network and partnerships in regenerative products, enabling broad market access. Lastly, RTI Surgical (US) and LifeNet Health (US) are considered lower-tier companies, with strengths in biologics, allografts, collagen-based grafts, and tissue regeneration technologies essential for dental reconstruction and guided bone regeneration.

Related Reports:

Dental Bone Graft Substitutes Market by Type (Xenograft, Allograft, Synthetic Bone Grafts, Alloplast), Application (Sinus Lift, Ridge Augmentation, Socket Preservation), Product (BioOss, Osteograf, Grafton), End User, Region - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com